Limits...
Peptidomic Identification of Serum Peptides Diagnosing Preeclampsia.

Wen Q, Liu LY, Yang T, Alev C, Wu S, Stevenson DK, Sheng G, Butte AJ, Ling XB - PLoS ONE (2013)

Bottom Line: We concluded that serum peptides can accurately discriminate active PE.Measurement of a 19-peptide panel could be performed quickly and in a quantitative mass spectrometric platform available in clinical laboratories.This serum peptide panel quantification could provide clinical utility in predicting PE or differential diagnosis of PE from confounding chronic hypertension.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Stanford University, Stanford, California, United States of America.

ABSTRACT
We sought to identify serological markers capable of diagnosing preeclampsia (PE). We performed serum peptide analysis (liquid chromatography mass spectrometry) of 62 unique samples from 31 PE patients and 31 healthy pregnant controls, with two-thirds used as a training set and the other third as a testing set. Differential serum peptide profiling identified 52 significant serum peptides, and a 19-peptide panel collectively discriminating PE in training sets (n = 21 PE, n = 21 control; specificity = 85.7% and sensitivity = 100%) and testing sets (n = 10 PE, n = 10 control; specificity = 80% and sensitivity = 100%). The panel peptides were derived from 6 different protein precursors: 13 from fibrinogen alpha (FGA), 1 from alpha-1-antitrypsin (A1AT), 1 from apolipoprotein L1 (APO-L1), 1 from inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4), 2 from kininogen-1 (KNG1), and 1 from thymosin beta-4 (TMSB4). We concluded that serum peptides can accurately discriminate active PE. Measurement of a 19-peptide panel could be performed quickly and in a quantitative mass spectrometric platform available in clinical laboratories. This serum peptide panel quantification could provide clinical utility in predicting PE or differential diagnosis of PE from confounding chronic hypertension.

No MeSH data available.


Related in: MedlinePlus

The serum concentrations of sFlt-1 (left) and PIGF (right) as a function of the gestation.For either PE (red) or control (green) data points, a loess curve was fitted to represent the overall trend of biomarker serum abundance as a function of gestation.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3686758&req=5

pone-0065571-g001: The serum concentrations of sFlt-1 (left) and PIGF (right) as a function of the gestation.For either PE (red) or control (green) data points, a loess curve was fitted to represent the overall trend of biomarker serum abundance as a function of gestation.

Mentions: Elevated soluble sFlt-1 and decreased PIGF levels are suggested in the pathogenesis of PE [15]–[21], and the sFlt-1/PIGF ratio has been proposed as a useful index in the diagnosis and management of PE [22], [23]. Our ELISA assay result (Figure 1) reproduced previous observations [22], [23]. With the range of gestation-week 24 to 40, the control PIGF serum concentrations increased continuously peaked around gestation week 30 and then decreased to the end of the pregnancy. The control sFlt-1 serum concentrations remained relatively stable trending slightly upwards with the gestation weeks. When comparing PE to control subjects, these two analytes' serum concentrations were differentiated with sFlt-1 significantly increased and PIGF significantly decreased throughout the gestation weeks. Our ELISA analysis results provided a sample qualification analysis indicating that our PE and control samples can be used to allow further biomarker discovery and testing analyses.


Peptidomic Identification of Serum Peptides Diagnosing Preeclampsia.

Wen Q, Liu LY, Yang T, Alev C, Wu S, Stevenson DK, Sheng G, Butte AJ, Ling XB - PLoS ONE (2013)

The serum concentrations of sFlt-1 (left) and PIGF (right) as a function of the gestation.For either PE (red) or control (green) data points, a loess curve was fitted to represent the overall trend of biomarker serum abundance as a function of gestation.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3686758&req=5

pone-0065571-g001: The serum concentrations of sFlt-1 (left) and PIGF (right) as a function of the gestation.For either PE (red) or control (green) data points, a loess curve was fitted to represent the overall trend of biomarker serum abundance as a function of gestation.
Mentions: Elevated soluble sFlt-1 and decreased PIGF levels are suggested in the pathogenesis of PE [15]–[21], and the sFlt-1/PIGF ratio has been proposed as a useful index in the diagnosis and management of PE [22], [23]. Our ELISA assay result (Figure 1) reproduced previous observations [22], [23]. With the range of gestation-week 24 to 40, the control PIGF serum concentrations increased continuously peaked around gestation week 30 and then decreased to the end of the pregnancy. The control sFlt-1 serum concentrations remained relatively stable trending slightly upwards with the gestation weeks. When comparing PE to control subjects, these two analytes' serum concentrations were differentiated with sFlt-1 significantly increased and PIGF significantly decreased throughout the gestation weeks. Our ELISA analysis results provided a sample qualification analysis indicating that our PE and control samples can be used to allow further biomarker discovery and testing analyses.

Bottom Line: We concluded that serum peptides can accurately discriminate active PE.Measurement of a 19-peptide panel could be performed quickly and in a quantitative mass spectrometric platform available in clinical laboratories.This serum peptide panel quantification could provide clinical utility in predicting PE or differential diagnosis of PE from confounding chronic hypertension.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Stanford University, Stanford, California, United States of America.

ABSTRACT
We sought to identify serological markers capable of diagnosing preeclampsia (PE). We performed serum peptide analysis (liquid chromatography mass spectrometry) of 62 unique samples from 31 PE patients and 31 healthy pregnant controls, with two-thirds used as a training set and the other third as a testing set. Differential serum peptide profiling identified 52 significant serum peptides, and a 19-peptide panel collectively discriminating PE in training sets (n = 21 PE, n = 21 control; specificity = 85.7% and sensitivity = 100%) and testing sets (n = 10 PE, n = 10 control; specificity = 80% and sensitivity = 100%). The panel peptides were derived from 6 different protein precursors: 13 from fibrinogen alpha (FGA), 1 from alpha-1-antitrypsin (A1AT), 1 from apolipoprotein L1 (APO-L1), 1 from inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4), 2 from kininogen-1 (KNG1), and 1 from thymosin beta-4 (TMSB4). We concluded that serum peptides can accurately discriminate active PE. Measurement of a 19-peptide panel could be performed quickly and in a quantitative mass spectrometric platform available in clinical laboratories. This serum peptide panel quantification could provide clinical utility in predicting PE or differential diagnosis of PE from confounding chronic hypertension.

No MeSH data available.


Related in: MedlinePlus